查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1497676

癌症生物标记市场：按生物标记类型、癌症类型、技术、应用、最终用户 - 2024-2030 年全球预测

Cancer Biomarkers Market by Biomarker Type (Genetic, Protein), Cancer Type (Blood Cancer, Breast Cancer, Colorectal Cancer), Technology, Application, End User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

癌症生物标记市场规模预计2023年为283.1亿美元，2024年达到312.3亿美元，预计2030年将达到577.5亿美元，复合年增长率为10.71%。

癌症生物标记是可以在身体部位（例如血液或组织）中测量的物质或过程，可以帮助检测体内是否有癌症。蛋白质、基因突变或其他分子显示身体可能正在对抗癌症。癌症生物标记的使用不断扩大，主要是由于技术进步提高了这些测试的准确性和速度。此外，人们对个人化医疗的认识不断提高，透过为每位患者提供量身定制的治疗来改善治疗结果，从而扩大了癌症生物标记的应用。然而，测试中的假阳性或假阴性可能导致错误的治疗决策，并可能对市场成长构成挑战。然而，目前难以早期检测的癌症类型（例如胰腺癌和卵巢癌）的生物标记的开拓有可能扩大市场扩张的范围。此外，将生物标记与数位健康资讯系统结合有可能增强患者监测和持续治疗协调。

主要市场统计
基准年[2023] 283.1亿美元
预测年份 [2024] 312.3亿美元
预测年份 [2030] 577.5亿美元
复合年增长率（%） 10.71%

区域洞察

在美洲，强大的医疗基础设施以及对癌症筛检和早期检测的高度认识正在推动对癌症生物标记的需求。该地区，尤其是美国，是许多致力于开发新生物标记并将其商业化的大型生物技术和医疗保健公司的所在地。该市场从政府的支持措施和研发方面的大量投资中受益匪浅。由于西欧完善的医疗保健系统以及中东和非洲国家政府对癌症研究的支持不断增加，EMEA（欧洲、中东和非洲）地区也是癌症生物标记的重要市场。由于医疗成本上升和癌症盛行率增加，亚太地区癌症生物标记领域呈现快速成长。中国、日本和印度等国家正大力投资医疗基础设施和研究，推动成长。此外，这些经济体的中产阶级人口不断增长，为实施先进的医疗保健解决方案（包括癌症生物标记）创造了巨大的机会。

FPNV定位矩阵

FPNV 定位矩阵对于评估供应商在癌症生物标记市场的定位至关重要。此矩阵提供了对供应商的全面评估，并检验了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果，供应商被分为代表其成功程度的四个像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可对癌症生物标记市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献，您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外，该分析还提供了对该领域竞争性质的宝贵见解，包括累积研究期、片段化优势和合併特征等因素。有了这些详细信息，供应商可以做出更明智的决策并製定有效的策略，以在市场竞争中保持领先地位。

策略分析与建议

策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对目前在癌症生物标记市场中的地位进行全面评估，使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析，以确定核心优势和需要改进的领域。

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 人群中癌症盛行率增加
      • 加大早期癌症检测的强度和宣传活动
      • 扩大医疗基础设施和医疗支出
    • 抑制因素
      • 研发成本高
    • 机会
      • 用于检测恶性肝癌的更好生物标记的出现
      • 积极的研究活动旨在引入新的生物标记以早期检测肺癌
    • 任务
      • 复杂且严格的监管合规
  • 市场区隔分析
    • 生物标记的类型：蛋白质生物标记物可效用透过血液和组织中所含的蛋白质检测癌症的存在
    • 应用：诊断中优先选择生物标记以进行早期检测，以改善患者的治疗结果
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章按生物标记类型分類的癌症生物标记市场

  • 遗传上
  • 蛋白质

第 7 章按癌症类型分類的癌症生物标记市场

  • 血癌
  • 乳癌
  • 大肠直肠癌
  • 肺癌
  • 卵巢癌
  • 摄护腺癌
  • 皮肤癌
  • 胃癌

第八章癌症生物标记市场：依技术分类

  • 生物资讯学
  • 细胞遗传学
  • 成像技术
  • 免疫学测试
  • 体学技术

第九章癌症生物标记市场：依应用分类

  • 诊断
  • 药物发现与开发
  • 预言
  • 风险评估

第 10 章癌症生物标记市场：按最终用户分类

  • 学术/癌症研究中心
  • 医院
  • 专业中心

第十一章美洲癌症生物标记市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区癌症生物标记市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲的癌症生物标记市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Chromacord 与乔治亚医学院结成策略联盟，加强 NSCLC 诊断能力
    • 晶泰科技与CK Life Sciences加强人工智慧合作，打造下一代癌症诊断
    • 提高癌症治疗的准确性：FDA启动试验计画来规范伴同性药物的伴随诊断测试
  • 战略分析和建议

第15章竞争组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-437517DB6E4D

[197 Pages Report] The Cancer Biomarkers Market size was estimated at USD 28.31 billion in 2023 and expected to reach USD 31.23 billion in 2024, at a CAGR 10.71% to reach USD 57.75 billion by 2030.

Cancer biomarkers are substances or processes that can be measured in parts of the body, such as blood or tissue, and help to detect the presence of cancer in the body. They can be proteins, genetic mutations, or other molecules that indicate the body may be fighting cancer. The use of cancer biomarkers is expanding primarily due to advancements in technology, which improve the accuracy and speed of these tests. Moreover, growing awareness of personalized medicine, which tailors treatment to individual patients and improves outcomes, has increased the applications of cancer biomarkers. However, false positives or negatives in tests, which can lead to incorrect treatment decisions, may challenge the market growth. Nevertheless, developing biomarkers for types of cancers that are currently hard to detect early, such as pancreatic or ovarian cancer, may increase the scope of market expansion. Additionally, integrating biomarkers with digital health information systems could enhance patient monitoring and ongoing treatment adjustments.

KEY MARKET STATISTICS
Base Year [2023] USD 28.31 billion
Estimated Year [2024] USD 31.23 billion
Forecast Year [2030] USD 57.75 billion
CAGR (%) 10.71%

Regional Insights

In the Americas, robust healthcare infrastructure and a high level of awareness about cancer screening and early detection drive the demand for cancer biomarkers. The region, especially the United States, is also home to numerous leading biotechnology and healthcare companies engaged in developing and commercializing new biomarkers. This marketplace benefits significantly from supportive government initiatives and substantial investment in research and development. EMEA also presents a substantial market for cancer biomarkers, supported by well-established healthcare systems in Western Europe and increasing government support for cancer research across the Middle Eastern and African countries. The Asia Pacific region showcases rapid growth in the cancer biomarkers field due to rising healthcare spending and the increasing prevalence of cancer. Countries such as China, Japan, and India are investing heavily in healthcare infrastructure and research, facilitating growth. Additionally, the expanding middle-class populations in these economies present a significant opportunity for the adoption of advanced healthcare solutions, including cancer biomarkers.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Cancer Biomarkers Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Increasing prevalence of cancer disorders among population
      • Rising initiatives and awareness campaigns for early cancer detection
      • Growing healthcare infrastructure and healthcare spending
    • Market Restraints
      • High costs associated with research and development
    • Market Opportunities
      • Emergence of better biomarkers for detection of aggressive liver cancer
      • Robust research activities to introduce new biomarkers for early detection of lung cancer
    • Market Challenges
      • Complex and stringent regulatory compliances
  • Market Segmentation Analysis
    • Biomarker Type: Usability of protein biomarkers in detecting the presence of cancer through proteins found in blood or tissue
    • Application: Preferences for biomarkers in diagnostic for early-stage detection to improve treatment outcomes for patients
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cancer Biomarkers Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cancer Biomarkers Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Strategic Collaboration between ChromaCode and Medical College of Georgia to Enhance NSCLC Diagnostic Capabilities

ChromaCode, Inc. and the Department of Pathology at the Medical College of Georgia have announced a partnership aimed at evaluating the performance of ChromaCode's innovative HDPCR assay for non-small cell lung cancer (NSCLC). This assay, endorsed for its comprehensive coverage of clinically relevant variants by the National Comprehensive Cancer Network, delivers rapid results with a 4-hour workflow and utilizes cloud-based analytics for quick interpretation. [Published On: 2024-03-20]

Enhanced AI Collaboration Between XtalPi and CK Life Sciences for Next-Generation Cancer Diagnostics

China-based XtalPi and CK Life Sciences are intensifying their joint efforts to utilize artificial intelligence (AI) to develop miRNA-based molecular diagnostic models tailored for postoperative cancer care. This collaboration aims to refine prognostic risk predictions by analyzing anonymized clinical data and biomarker information sourced from both cancer patients and healthy individuals within CK's extensive database. [Published On: 2023-11-06]

Enhancing Precision in Cancer Treatment: FDA Initiates Pilot Program to Regulate Companion Diagnostic Tests for Oncology Drugs

The U.S. Food and Drug Administration (FDA) has introduced a pivotal pilot program focused on refining the integration of specific oncology drugs with their corresponding in-vitro diagnostic tests. This initiative primarily addresses the critical use of laboratory-developed tests (LDTs), which have yet to undergo the FDA's extensive review for safety or effectiveness. The program aims to establish and make public the minimum performance characteristics necessary for diagnostic tests utilized in clinical trials. [Published On: 2023-06-21]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cancer Biomarkers Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Cancer Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories Inc., Agilent Technologies, Inc., ASURAGEN, INC., Bio-Rad Laboratories, Inc., bioMerieux SA, Bristol-Myers Squibb Company, Bruker Corporation, Charles River Laboratories International, Inc., Enzo Biochem, Inc., Epigenomics AG, Eurofins Scientific SE, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies Inc., Hologic, Inc., Illumina, Inc., Merck KGaA, Myriad Genetics, Inc., PerkinElmer, Inc., Pfizer Inc., QIAGEN N.V, Quest Diagnostics Incorporated, Siemens Healthcare GmbH, Sysmex Corporation, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Cancer Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Biomarker Type
    • Genetic
    • Protein
  • Cancer Type
    • Blood Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
    • Ovarian Cancer
    • Prostate Cancer
    • Skin Cancer
    • Stomach Cancer
  • Technology
    • Bioinformatics
    • Cytogenetics
    • Imaging Technology
    • Immunoassays
    • OMICS Technology
  • Application
    • Diagnostics
    • Drug Discovery & Development
    • Prognostics
    • Risk Assessment
  • End User
    • Academic & Cancer Research Centers
    • Hospitals
    • Speciality Centers
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer disorders among population
      • 5.1.1.2. Rising initiatives and awareness campaigns for early cancer detection
      • 5.1.1.3. Growing healthcare infrastructure and healthcare spending
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with research and development
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of better biomarkers for detection of aggressive liver cancer
      • 5.1.3.2. Robust research activities to introduce new biomarkers for early detection of lung cancer
    • 5.1.4. Challenges
      • 5.1.4.1. Complex and stringent regulatory compliances
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Biomarker Type: Usability of protein biomarkers in detecting the presence of cancer through proteins found in blood or tissue
    • 5.2.2. Application: Preferences for biomarkers in diagnostic for early-stage detection to improve treatment outcomes for patients
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Cancer Biomarkers Market, by Biomarker Type

  • 6.1. Introduction
  • 6.2. Genetic
  • 6.3. Protein

7. Cancer Biomarkers Market, by Cancer Type

  • 7.1. Introduction
  • 7.2. Blood Cancer
  • 7.3. Breast Cancer
  • 7.4. Colorectal Cancer
  • 7.5. Lung Cancer
  • 7.6. Ovarian Cancer
  • 7.7. Prostate Cancer
  • 7.8. Skin Cancer
  • 7.9. Stomach Cancer

8. Cancer Biomarkers Market, by Technology

  • 8.1. Introduction
  • 8.2. Bioinformatics
  • 8.3. Cytogenetics
  • 8.4. Imaging Technology
  • 8.5. Immunoassays
  • 8.6. OMICS Technology

9. Cancer Biomarkers Market, by Application

  • 9.1. Introduction
  • 9.2. Diagnostics
  • 9.3. Drug Discovery & Development
  • 9.4. Prognostics
  • 9.5. Risk Assessment

10. Cancer Biomarkers Market, by End User

  • 10.1. Introduction
  • 10.2. Academic & Cancer Research Centers
  • 10.3. Hospitals
  • 10.4. Speciality Centers

11. Americas Cancer Biomarkers Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Cancer Biomarkers Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Cancer Biomarkers Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Strategic Collaboration between ChromaCode and Medical College of Georgia to Enhance NSCLC Diagnostic Capabilities
    • 14.3.2. Enhanced AI Collaboration Between XtalPi and CK Life Sciences for Next-Generation Cancer Diagnostics
    • 14.3.3. Enhancing Precision in Cancer Treatment: FDA Initiates Pilot Program to Regulate Companion Diagnostic Tests for Oncology Drugs
  • 14.4. Strategy Analysis & Recommendation

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CANCER BIOMARKERS MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER BIOMARKERS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CANCER BIOMARKERS MARKET DYNAMICS
  • FIGURE 7. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. CANCER BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. CANCER BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER BIOMARKERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER BIOMARKERS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CANCER BIOMARKERS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY GENETIC, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY GENETIC, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROTEIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROTEIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY LUNG CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY SKIN CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY SKIN CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CYTOGENETICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CYTOGENETICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY OMICS TECHNOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY OMICS TECHNOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY ACADEMIC & CANCER RESEARCH CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY ACADEMIC & CANCER RESEARCH CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY SPECIALITY CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY SPECIALITY CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 78. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 79. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 80. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 83. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 88. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 89. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 90. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 91. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 92. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 93. CANADA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. CANADA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. CANADA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. CANADA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. CANADA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 98. CANADA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 99. CANADA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 100. CANADA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 101. CANADA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 102. CANADA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 103. MEXICO CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. MEXICO CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. MEXICO CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. MEXICO CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. MEXICO CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 108. MEXICO CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 109. MEXICO CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 110. MEXICO CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 111. MEXICO CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 112. MEXICO CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 113. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 118. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 119. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 120. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 121. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 122. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 123. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 124. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 142. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 144. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 146. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 147. CHINA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. CHINA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. CHINA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. CHINA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. CHINA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 152. CHINA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 153. CHINA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 154. CHINA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 155. CHINA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 156. CHINA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 157. INDIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. INDIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. INDIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. INDIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. INDIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 162. INDIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 163. INDIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 164. INDIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 165. INDIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 166. INDIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 167. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 172. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 173. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 174. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 175. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 176. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 177. JAPAN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. JAPAN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. JAPAN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. JAPAN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. JAPAN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 182. JAPAN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 183. JAPAN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 184. JAPAN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 185. JAPAN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 186. JAPAN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 187. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 192. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 193. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 194. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 195. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 196. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 202. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 203. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 204. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 205. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 206. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 207. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 212. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 213. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 214. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 215. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 216. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 220. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 221. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 222. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 223. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 224. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 225. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 226. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 227. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 228. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 229. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 232. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 233. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 234. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 235. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 236. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 237. THAILAND CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. THAILAND CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. THAILAND CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. THAILAND CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. THAILAND CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 242. THAILAND CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 243. THAILAND CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 244. THAILAND CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 245. THAILAND CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 246. THAILAND CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 247. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 252. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 253. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 254. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 255. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 256. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 269. DENMARK CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. DENMARK CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. DENMARK CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. DENMARK CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. DENMARK CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 274. DENMARK CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 275. DENMARK CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 276. DENMARK CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 277. DENMARK CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 278. DENMARK CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 279. EGYPT CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. EGYPT CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. EGYPT CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 282. EGYPT CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 283. EGYPT CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 284. EGYPT CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 285. EGYPT CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 286. EGYPT CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 287. EGYPT CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 288. EGYPT CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 289. FINLAND CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 290. FINLAND CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 291. FINLAND CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 292. FINLAND CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 293. FINLAND CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 294. FINLAND CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 295. FINLAND CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 296. FINLAND CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 297. FINLAND CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 298. FINLAND CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 299. FRANCE CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 300. FRANCE CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 301. FRANCE CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 302. FRANCE CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 303. FRANCE CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 304. FRANCE CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 305. FRANCE CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 306. FRANCE CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 307. FRANCE CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 308. FRANCE CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 309. GERMANY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 310. GERMANY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 311. GERMANY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 312. GERMANY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 313. GERMANY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 314. GERMANY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 315. GERMANY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 316. GERMANY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 317. GERMANY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 318. GERMANY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 319. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 320. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 321. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 322. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 323. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 324. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 325. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 326. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 327. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 328. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 329. ITALY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 330. ITALY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 331. ITALY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 332. ITALY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 333. ITALY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 334. ITALY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 335. ITALY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 336. ITALY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 337. ITALY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 338. ITALY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 339. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 340. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 341. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 342. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 343. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 344. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 345. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 346. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 347. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 348. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 349. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 350. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 351. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 352. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 353. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 354. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 355. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 356. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD M